News

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Merck buys Raleigh pharma company for $10 billion, drawn by new COPD drug
Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
Merck & Co.: A Pharma Titan At A Discount
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
Two big reasons why buying Verona was crucial for Merck
Merck announces plans of buying Verona for a huge premium. VRNA deal could shield Merck from two major headwinds.
Pharmabiz17m
Merck Animal Health’s Bravecto Quantum receives US FDA approval to treat and protect dogs from fleas and ticks
Rahway, New Jersey Saturday, July 12, 2025, 09:00 Hrs [IST] ...
UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...
MONTCO Today on MSN17h
WSJ: Merck Makes $10 Billion Move as Keytruda Patent Expiration Nears
Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...
BioPharma Dive12h
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...